{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018936","form_type":"8-K","ticker":"RLYB","cik":"0001739410","company_name":"Rallybio Corp","filed_at":"2022-09-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.868088+00:00","generated_at":"2026-06-23T07:00:28.449866+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rallybio: RLYB212 Phase 1b rapidly eliminates HPA-1a platelets; proof-of-concept data Q1 2023","bullets":["RLYB212 showed >90% reduction in mean platelet elimination half-life vs placebo in Phase 1b.","Single subcutaneous dose eliminated transfused HPA-1a positive platelets rapidly one week after dosing.","No serious adverse events; safety and tolerability acceptable.","Protocol amended to increase dose and expand PK/PD sampling; registrational trial dosing expected to be informed.","Proof-of-concept data from Phase 1b study expected in Q1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018936","json":"https://secwatch.observer/filing/0000950170-22-018936.json","markdown":"https://secwatch.observer/filing/0000950170-22-018936.md","text":"https://secwatch.observer/filing/0000950170-22-018936.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022018936/0000950170-22-018936-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1739410/000095017022018936/rlyb-20220928.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T07:00:28.449866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}